Gynaecomastia vs breast cancer is a distinction that matters enormously for any male noticing breast swelling or a lump. Gynaecomastia — the benign enlargement of glandular breast tissue — is common and not cancerous, yet it can be difficult to tell apart from male breast cancer on appearance alone. Male breast cancer is rare, accounting for fewer than 1% of UK breast cancer diagnoses, but it is serious and outcomes are far better when caught early. This article explains the key differences in symptoms, diagnosis, risk factors, and treatment, helping men make informed decisions about when to seek medical advice.

Understanding Gynaecomastia and Male Breast Cancer

Gynaecomastia is a common benign condition caused by oestrogen–androgen imbalance, whereas male breast cancer is rare but serious, accounting for fewer than 1% of UK breast cancer diagnoses; both can present as breast swelling, making clinical distinction essential.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia is the benign enlargement of glandular breast tissue in males, affecting one or both breasts. It is a common condition, estimated to affect up to 65% of adolescent boys and a significant proportion of older men, though prevalence figures vary across studies. Despite causing understandable concern, gynaecomastia is not cancerous. In most cases it does not increase the risk of developing breast cancer; however, certain underlying conditions associated with gynaecomastia — such as Klinefelter syndrome or BRCA2 gene mutations — do independently confer an elevated breast cancer risk. Gynaecomastia itself arises from an imbalance between oestrogen and androgen activity in breast tissue, leading to proliferation of the ductal and stromal components.

Male breast cancer, by contrast, is rare but serious. According to Cancer Research UK, it accounts for less than 1% of all breast cancer diagnoses in the UK, with approximately 400 new cases recorded each year. The most common type is invasive ductal carcinoma, which originates in the milk ducts. Because men are generally less aware of breast cancer as a personal risk, diagnoses can sometimes occur at a more advanced stage, making awareness particularly important.

Both conditions present as breast swelling or a palpable lump, which is why they are frequently confused. However, their underlying biology, clinical behaviour, and management differ substantially. Understanding these distinctions helps patients seek timely and appropriate medical attention, and supports clinicians in making accurate assessments during initial consultations.

Key Differences in Symptoms and Physical Signs

Gynaecomastia typically presents as soft, mobile, subareolar tissue that may be tender, whilst male breast cancer more often presents as a hard, irregular, fixed, or eccentric lump with nipple changes or skin dimpling — features that meet NICE NG12 urgent referral criteria.

Distinguishing gynaecomastia from male breast cancer on clinical grounds alone can be challenging, but several features help differentiate the two conditions. Gynaecomastia typically presents as:

• Bilateral or unilateral soft, rubbery, or firm disc-shaped tissue directly beneath the nipple-areolar complex

• Symmetrical subareolar position, often tender or mildly painful, particularly in adolescents

• Smooth, mobile tissue that moves freely under the skin

• Gradual onset, often associated with puberty, weight gain, or medication use

Male breast cancer, on the other hand, tends to display more concerning features. These include:

• A hard, irregular, or fixed lump, often eccentric (off-centre from the nipple)

• Unilateral presentation in the vast majority of cases

• Nipple changes such as inversion or retraction (particularly if new), discharge (especially if blood-stained or spontaneous), or ulceration — these features meet urgent referral criteria under NICE guideline NG12

• Skin changes including dimpling, puckering, or a peau d'orange (orange-peel) texture

• Painless in many cases, though pain does not exclude malignancy

• Possible axillary lymph node enlargement

Pain or tenderness is more commonly associated with gynaecomastia than with cancer, though this is not a reliable distinguishing feature on its own. Importantly, clinical examination alone cannot exclude malignancy. Any new, persistent, or changing breast lump in a male patient warrants prompt clinical evaluation, regardless of whether it appears benign. Self-reassurance based on symptom characteristics alone is not advisable, and a GP assessment remains the appropriate first step.

How Each Condition Is Diagnosed in the NHS

NHS diagnosis of a male breast lump follows the triple assessment protocol — clinical examination, imaging (ultrasound and/or mammography), and core needle biopsy — with urgent two-week wait referral if malignancy is suspected under NICE guideline NG12.

In the NHS, the diagnostic pathway for a male breast lump typically begins with a GP consultation. If the GP identifies features suggestive of malignancy, the patient should be referred under the two-week wait (2WW) urgent cancer referral pathway to a specialist breast clinic, in line with NICE guideline NG12. This ensures assessment within 14 days of referral.

At the breast clinic, the standard approach follows the triple assessment protocol:

1. Clinical examination — a thorough physical assessment of the breast, nipple, and regional lymph nodes
2. Imaging — the choice of modality varies by centre and is guided by local protocols and Association of Breast Surgery (ABS) or Royal College of Radiologists (RCR) guidance. Ultrasound is commonly used as the first-line investigation in younger men, whilst mammography combined with ultrasound may be preferred in older men. Ultrasound is particularly useful for differentiating solid from cystic lesions and assessing tissue characteristics
3. Tissue sampling — where imaging raises concern, a core needle biopsy is the preferred method for obtaining tissue for pathological analysis, as it provides histological rather than cytological material. Fine needle aspiration cytology (FNAC) is used less frequently

For gynaecomastia, the diagnosis is largely clinical. Blood tests may be requested to identify an underlying hormonal cause, including:

• Serum testosterone, LH, FSH, and oestradiol to assess gonadal function

• Thyroid function tests (TSH and free T4), as hyperthyroidism is a recognised cause

• Prolactin levels if a pituitary cause is suspected

• Liver function tests and renal function, as hepatic and renal disease can contribute

• hCG (and AFP where a testicular germ cell tumour is suspected) to exclude this important cause

Testicular ultrasound may be arranged where there is a palpable testicular abnormality, elevated hCG, or unexplained endocrine abnormality. The distinction between gynaecomastia and pseudogynaecomastia (fatty tissue deposition without glandular proliferation, common in obesity) is made clinically and, where necessary, with ultrasound.

Risk Factors and Who Is Most Affected

Gynaecomastia is most common in neonates, adolescents, and older men, often linked to medications or hormonal conditions, whilst male breast cancer risk is highest in men over 60 with BRCA2 mutations, Klinefelter syndrome, or a relevant family history.

Gynaecomastia has a broad range of causes and affects males across all age groups, though it is most prevalent during three distinct life stages: neonatal (due to maternal oestrogen), pubertal (hormonal fluctuation), and older adulthood (declining testosterone with relative oestrogen excess). Specific risk factors include:

• Medications — a significant and often overlooked cause. Implicated drugs include spironolactone, cimetidine, digoxin, anabolic steroids, anti-androgens (e.g., bicalutamide used in prostate cancer), 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride), certain antiretrovirals (e.g., efavirenz), ketoconazole, verapamil, and some antipsychotics and antidepressants

• Recreational substances — alcohol and anabolic steroid misuse are recognised contributors. Cannabis has been suggested as a possible cause in some reports, though the evidence is of low certainty and this association remains debated

• Medical conditions — hypogonadism, hyperthyroidism, chronic liver disease, chronic kidney disease, and adrenal tumours

• Obesity — increases peripheral conversion of androgens to oestrogens via aromatase activity in adipose tissue

Male breast cancer risk factors differ considerably and include:

• Age — most cases occur in men over 60

• BRCA2 gene mutations — the most significant hereditary risk factor; BRCA2 carriers have a substantially elevated lifetime risk (estimated at approximately 6–8% in some studies), as outlined in NICE guideline CG164 on familial breast cancer

• Klinefelter syndrome (47,XXY) — associated with a markedly elevated risk due to hypogonadism and elevated oestrogen levels

• Family history of breast cancer in first-degree relatives

• Previous chest wall radiation

• Liver cirrhosis and conditions causing elevated oestrogen

• Obesity

While gynaecomastia itself is not considered a direct risk factor for male breast cancer, both conditions can coexist, and any change in a pre-existing gynaecomastia should be re-evaluated clinically.

When to See a GP and What to Expect

Men should contact their GP promptly for any new, hard, irregular, or changing breast lump, nipple discharge, or skin changes; the GP will take a history, examine the breast, and decide whether urgent two-week wait referral under NICE NG12 is warranted.

Men are often reluctant to seek medical advice about breast changes due to embarrassment or a belief that breast conditions are exclusively female concerns. However, early presentation is associated with significantly better outcomes in breast cancer, making prompt consultation essential.

You should contact your GP promptly if you notice:

• Any new lump in the breast or underarm area

• A lump that is hard, irregular, or fixed to surrounding tissue

• Nipple discharge, particularly if blood-stained or spontaneous

• Nipple inversion or retraction that is new

• Skin changes over the breast, including dimpling or redness

• A lump that is growing or changing in character

• Breast swelling associated with unexplained weight loss, fatigue, or bone pain

For gynaecomastia, a GP appointment is still advisable, particularly if the swelling is persistent (beyond one to two years in adolescents), painful, rapidly enlarging, or associated with other symptoms such as reduced libido or erectile dysfunction that may suggest an underlying hormonal disorder.

At the GP appointment, you can expect a thorough history — including medication review, family history, and symptom timeline — followed by a physical examination. The GP will assess whether urgent referral under the two-week wait pathway (NICE NG12) is warranted, or whether initial blood tests and watchful waiting are more appropriate. Patients referred urgently to a breast clinic should be seen within two weeks. The NHS breast clinic team will explain each step of the triple assessment process clearly. Result turnaround times vary by service, so it is reasonable to ask your clinical team when and how you will receive your results.

Treatment Options and Outlook for Both Conditions

Gynaecomastia often resolves spontaneously or with removal of the causative drug; persistent cases may be treated off-label with tamoxifen or surgery. Male breast cancer is primarily treated with mastectomy, adjuvant tamoxifen for ER-positive disease, and radiotherapy, with excellent outcomes when detected early.

The management of gynaecomastia depends on its underlying cause, severity, and duration. In many cases, particularly in adolescent boys, watchful waiting is appropriate, as the condition resolves spontaneously within one to two years in the majority of cases. Where a causative medication is identified, discontinuing or substituting the offending drug often leads to gradual resolution.

For persistent or symptomatic gynaecomastia, treatment options include:

• Medical therapy — selective oestrogen receptor modulators (SERMs) such as tamoxifen or raloxifene may be considered, but it is important to note that neither is licensed in the UK specifically for gynaecomastia; their use in this context is off-label and should be initiated and supervised by a specialist. Medical therapy is most likely to be effective in the early, active (proliferative) phase, generally within approximately six to twelve months of onset. Key adverse effects include an increased risk of venous thromboembolism, hot flushes, and, with tamoxifen, endometrial changes. Aromatase inhibitors have shown limited benefit in gynaecomastia and are not routinely recommended. If you are prescribed any medicine for gynaecomastia, you can report suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or using the Yellow Card app

• Surgical intervention — subcutaneous mastectomy or liposuction-assisted surgery may be considered for longstanding, fibrotic gynaecomastia that has not responded to medical treatment, or where psychological distress is significant. NHS funding for gynaecomastia surgery is not universally available and is subject to local Integrated Care Board (ICB) commissioning policies; your GP or specialist can advise on what is available in your area

For male breast cancer, treatment is guided by tumour stage, receptor status, and the patient's overall health. The majority of male breast cancers are oestrogen receptor (ER)-positive, which has important therapeutic implications. Standard treatment approaches include:

• Surgery — mastectomy (with or without sentinel lymph node biopsy) is the primary surgical treatment

• Adjuvant radiotherapy — recommended following surgery depending on tumour size, margins, and nodal involvement

• Hormonal therapy — tamoxifen is the standard adjuvant endocrine therapy for ER-positive disease and is typically prescribed for five to ten years. Where tamoxifen is contraindicated or not tolerated, an aromatase inhibitor combined with a GnRH analogue may be considered

• Chemotherapy and targeted therapy — used in higher-risk or HER2-positive cases

The outlook for male breast cancer is closely linked to stage at diagnosis. According to Cancer Research UK, five-year survival rates are high for early-stage disease but fall significantly with advanced-stage presentation, reinforcing the importance of early detection. Gynaecomastia, when properly managed, carries an excellent prognosis with no impact on life expectancy.

Frequently Asked Questions